Journal article icon

Journal article

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial

Abstract:

Background: No randomised study has shown whether stratification of treatment by minimal residual disease (MRD) response improves outcome in children and young people with acute lymphoblastic leukaemia (ALL). We assessed whether children and young people with clinical standard and intermediate-risk ALL who have persistent MRD at the end of induction therapy benefit from augmented post-remission therapy. Methods: Between Oct 1, 2003, and June 30, 2011, we enrolled eligible patients aged 1-24 y...

Expand abstract

Actions


Access Document


Authors


Publisher:
Lancet
Journal:
Lancet Oncology More from this journal
Volume:
15
Issue:
8
Pages:
809-818
Publication date:
2014-01-01
DOI:
EISSN:
1474-5488
ISSN:
1470-2045
Language:
English
Pubs id:
pubs:476795
UUID:
uuid:1af30eb3-2836-423e-8c1e-fa829e8b74cb
Local pid:
pubs:476795
Source identifiers:
476795
Deposit date:
2014-08-11

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP